Federal HIV guidelines add Bixlenvo as a switch option, back statins for adults 40 to 75 and urge clinicians to challenge payer barriers to antiretroviral therapy (ART).
News|Slideshows|October 29, 2026
HIV pipeline shifts toward weekly, monthly and twice-yearly dosing
Author(s)Logan Lutton
The FDA has approved three HIV products since June 2025, and the late-stage pipeline is testing how far apart doses can be spaced. Here are the milestones payers and health systems should track through 2027.
Advertisement
Health plans and health systems have spent the past year absorbing three new HIV approvals, and the next round of decisions is close.
Since June 2025, the FDA has approved Gilead's twice-yearly Yeztugo for prevention and two once-daily switch regimens, Merck's Idvynso and Gilead's Bixlenvo.
Late-stage programs from Gilead, Merck and ViiV Healthcare are now testing weekly and monthly pills and injections given every four or six months, and the FDA is due to act on a once-weekly oral form of lenacapavir for prevention by Feb. 2, 2027.
For payers, these products raise questions that go beyond efficacy. They include whether coverage falls under the medical or pharmacy benefit, how to set switching criteria for patients who are already suppressed and how to weigh sponsor-run comparisons that are arriving ahead of independent data. The following slides recap recent approvals and lay out the milestones plans should factor into formulary and benefit planning through 2027.
Advertisement
Related to this article
As pulmonary fibrosis treatment options grow, Rachael Prusi of Prime Therapeutics says health plans should lean on guidelines and strong case management.
Patients with pulmonary fibrosis wait about two years for a diagnosis. Rachael Prusi of Prime Therapeutics explains how health plans can find them sooner.
Hiva Pourarsalan at AMCP Nexus explains how MFP shifts Medicare drug pricing, disrupting rebates and contracting and forcing payers to rethink formularies.
EHRs miss many cancer deaths. Linking electronic health records with claims and third‑party death data sharply improves accuracy, Tempus reports at AMCP Nexus.
CMS projects roughly 2.3 million people will lose Medicaid coverage in 2027 under the new community engagement requirements, also referred to as work requirements: four in ten to paperwork, not noncompliance. Arkansas showed how that happens; here is what plans can learn before the clock starts.
Managed care leaders should vet AI tools before use and recheck them over time, and pharmacists need AI literacy, according to two AMCP Nexus 2026 presenters.
AI is speeding up managed care pharmacy work, but two pharmacists say human review remains key when tools affect patients' access to medications.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
5 things you should know about the midterms and healthcare
2
Prime's Pat Gleason flags cost, timing gaps in type 1 diabetes screening | AMCP Nexus 2026
3
5 things you should know about intismeran, the Moderna-Merck cancer vaccine
4
Narcolepsy type 1 drives 5-fold higher costs in first year after diagnosis
5